INVENTING A NEW
ROADMAP FOR BIOTECH
Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
FOR 30 YEARS, OUR
MISSION HAS BEEN TO
USE THE POWER OF
SCIENCE TO BRING
NEW MEDICINES TO
PATIENTS... OVER
AND OVER AGAIN.
Check out our 2018 annual materials. The Responsibility Report and Annual Report are now online.
Read our annual report
and responsibility report
REGENERON BY THE NUMBERS
-
30
years of scientific
leadership -
7,300+
employees
worldwide -
700+
employees with
an MD, PhD or
PharmD degree -
6TH
consecutive year
in Forbes' World's
Most Innovative
Companies -
#1
ranking in Science
magazine’s global Top
Employer survey for six
of the past eight years -
31,000+
employee volunteer hours
for 100+ organizations
in 2018 -
7
FDA-approved
medicines -
94%
of our waste
diverted from
landfill, reaching
our goal -
100%
of drug candidates
invented and
developed in-house -
100+
publications in 2018 -
20
product candidates in
clinical development
across multiple
therapeutic areas
-
Shingo Institute: The Shingo Prize, 2019
Great Places to Work: Best Workplace in Ireland, 2019
Science: #1 Top Employer, 2018
Forbes: Top 10 Most Innovative Companies, 2018
Civic 50: Most Community-Minded Companies in the Nation, 2018
Fortune: Best Companies to Work for, 2018
-
MIT Technology Review: Top 10 Smartest Companies, 2017
Fortune: Future 50, 2017
Barron’s: World’s Best CEOs, 2016
Scrip Award: R&D Team of the Year, 2016
Crain’s New York Business: Fast 50, 2015
LEADERSHIP
We are the only biopharmaceutical company to be led by physician-scientists for more than 30 years. We consistently demonstrate our commitment to scientific excellence by counting multiple Nobel Laureates and five members of the National Academy of Sciences among our leadership, as well as being one of the first companies to form a Science and Technology Committee as an integral component of its Board, a practice which has since become industry standard.
A FOCUS
ON SCIENCE
From our first days, science has remained our central guiding principle.